80 GUEST STREET, BOSTON, MA
Announces Pricing of Upsized $120 Million Public Offering
Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Shareholder votes
Reports 2025 First Quarter Financial Results and Provides Corporate Update
Annual Report to Security Holders
Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Reports 2024 Financial Results and Provides Corporate Update
Provides Corporate Update and Announces Advancement of a New Drug Candidate
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities